Shanghai Bio-heart Biological Technology Co., Ltd.

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023

In its 2023 reporting, Shanghai Bio-heart Biological Technology Co., Ltd. disclosed greenhouse gas emissions of 635.72 tCO2e/year. By scope: Scope 1: 18.54 tCO2e/year; Scope 2: 553.25 tCO2e/year; Scope 3: 59.18 tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
635.72 tCO2e/year
2023
💧
Water Usage
1.6K m3/year
2023
♻️
Waste
0.84 tons/year (0.24 hazardous, 0.70 non-hazardous)
2023
⚙️
Energy Use
968.60 MWh/year
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).18.54 tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.553.25 tCO2e/year
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).59.18 tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • General reduction of 1% in overall hazardous waste and non-hazardous waste intensity in the upcoming three years.
  • General reduction of 1% in overall energy use intensity in the upcoming three years.
  • General reduction of 1% in overall water use intensity in the upcoming three years.
  • General reduction of 1% in overall emission intensity in the upcoming three years.

🌱 ESG Focus Areas

Innovation and TechnologyQuality and Safety of Products and ServicesIntellectual Property ProtectionBusiness Ethics and IntegrityRisk Management

⚠️ Challenges & Risks +

  • Significant operating losses since inception and potential need for additional financing.
  • Lengthy and expensive clinical product development process with uncertain outcomes.
  • Limited experience in sales and marketing activities.
  • Extensive government regulations and unpredictable approval processes.
  • Complex manufacturing process subject to strict quality controls.
  • Reliance on a limited number of suppliers.
  • Potential product liability claims.
  • Competition in the medical device market.
  • Risks associated with doing business in China (political and economic changes, legal system uncertainties).

📋 Report Information

Reporting Period: 2023
Frameworks: Appendix C2 of the Rules Governing the Listing of Securities (the “Listing Rules”) issued by the Stock Exchange of Hong Kong Limited